NewGenIvf Group (NASDAQ:NIVF) Director Kong Yiu Cheung Buys 500,000 Shares

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung acquired 500,000 shares of NewGenIvf Group stock in a transaction dated Thursday, June 18th. The shares were bought at an average cost of $1.33 per share, for a total transaction of $665,000.00. Following the completion of the purchase, the director directly owned 1,222,223 shares of the company’s stock, valued at approximately $1,625,556.59. The trade was a 69.23% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Kong Yiu Cheung also recently made the following trade(s):

• On Monday, July 27th, Kong Yiu Cheung acquired 2,500,000 shares of NewGenIvf Group stock. The stock was bought at an average price of $1.00 per share, for a total transaction of $2,500,000.00.

NewGenIvf Group Trading Down 9.0%

NASDAQ NIVF opened at $1.21 on Thursday. NewGenIvf Group Limited has a 1-year low of $1.15 and a 1-year high of $1,539.00. The stock has a 50-day moving average of $2.87 and a 200-day moving average of $11.16. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.12 and a quick ratio of 2.98.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on NIVF shares. Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a report on Friday, July 24th. Wall Street Zen raised shares of NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, NewGenIvf Group currently has a consensus rating of “Sell”.

About NewGenIvf Group

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.